Australian respiratory imaging pioneer 4DMedical (ASX:4DX) has strengthened its balance sheet with a $22.6 million capital injection following the near-total exercise of its deep in-the-money 4DXOA options.
The company reported that 99.7 per cent of these options, priced at $0.55 each, were exercised before the deadline, significantly boosting its cash reserves. Combined with a recent $10 million strategic investment from Pro Medicus and a $6 million R&D Tax Incentive, 4DMedical’s pro forma 30 June 2025 cash balance now stands at $45.5 million.
The additional funds will provide the company with a solid financial runway to execute its strategic and commercial priorities, including expanding commercial adoption of its CT:VQ imaging solution, growing its presence across US healthcare systems, academic centres, and community radiology networks through its reseller partnership with Philips, and advancing post-FDA clearance studies while developing new clinical applications across its expanding imaging portfolio.
4DMedical also noted further potential capital inflows from its ASX:4DXO quoted options, which are currently in the money and set to expire on 31 December 2025. If fully exercised, these options could generate an additional $30.2 million in funding.
Managing Director and CEO Professor Andreas Fouras said September had been “a great month for 4DMedical and our shareholders,” adding that the strong support “has secured the capital required to execute on our commercialisation plans, most notably relating to CT:VQ.” Fouras said preparations were underway for a significant presence at RSNA 2025, the world’s largest radiology conference, scheduled to take place in late November.
4DMedical is working to redefine respiratory care with its patented XV Technology, which transforms standard medical scans into rich, functional insights on lung ventilation and perfusion. Its product suite utilises advanced AI to provide clinicians with faster and more precise diagnostic tools for lung disease detection and monitoring. Delivered via a Software-as-a-Service (SaaS) model, the company’s solutions integrate with hospital systems, offering scalability and real-time clinical utility.